Robert C. Field, a director at FIRST US BANCSHARES, INC. (NASDAQ:FUSB), recently purchased $19,121 worth of the company's common stock on September 8 and 9, 2026. These transactions involved 284 shares at $16.47 and 877 shares at a weighted average price between $16.47 and $16.48, respectively. Following these acquisitions, Mr. Field indirectly holds 13,274 shares, as FUSB trades near its 52-week high, despite an InvestingPro analysis suggesting it is overvalued.

SolarEdge Technologies saw its stock fall 4% on its Analyst Day, even after announcing a joint white paper with NVIDIA on 800 VDC power architecture for AI data centers. This decline occurred while solar peers like Enphase Energy and First Solar saw gains, suggesting the market is looking for concrete revenue timing and customer details rather than just lab results. While SolarEdge's core business shows a turnaround with revenue growth and improved gross margin, its AI data center segment still needs commercial proof to justify its valuation.

The Texas Stock Exchange (TXSE) has secured its first four company listings from major backer Kelcy Warren. Energy Transfer LP, along with three controlled entities—Sunoco LP, SunocoCorp LP, and USA Compression LP—will move their listings to TXSE in early October, representing nearly $100 billion in combined market capitalization. This move, following a "Dexit" trend of companies redomiciling to Texas, marks a significant milestone for TXSE and positions Texas as a growing leader in capital markets.

AbbVie's immunology franchise, driven by Skyrizi and Rinvoq, is a major growth engine, with sales exceeding half of the company's total revenue in the first half of 2026. These drugs have successfully replaced the revenue loss from Humira's biosimilar erosion, and AbbVie anticipates combined Skyrizi and Rinvoq sales to surpass $31 billion in 2026. The company is also actively expanding its immunology pipeline through internal R&D, acquisitions, and collaborations, despite the highly competitive market with other pharmaceutical giants.

Applied Materials' CEO Gary Dickerson asserts that the AI boom is far from over, backed by the company's strong order book showing rolling eight-quarter forecasts from customers and commitments extending to 2030. The company anticipates nearly 40% growth this year, driven by AI compute demand, with significant contributions from DRAM and advanced packaging. While the stock has seen substantial gains, its current valuation suggests much of the bullish sentiment is already priced in, making pullbacks a potential entry point.

Robert C. Field, a director at First US Bancshares (NASDAQ:FUSB), recently purchased $19,121 worth of the company's common stock over two days, acquiring 284 shares at $16.47 and an additional 877 shares at a weighted average price of $16.47. These transactions increase his indirect holdings to 13,274 shares through Highland Mortgage, LLC. The purchases occurred as FUSB's stock trades near its 52-week high, despite an InvestingPro analysis suggesting the stock is overvalued relative to its Fair Value but maintains a low P/E ratio of 12.6.

Nvidia CEO Jensen Huang expressed strong confidence in the company's continued rapid expansion, citing ongoing momentum in AI infrastructure. The article highlights Huang's unwavering conviction in Nvidia's future trajectory.

Hexagon Energy and Weyerhaeuser Co. have signed an agreement to develop geothermal projects in Washington and Oregon, aiming for an estimated 3 GW of power generation capacity. This collaboration leverages Weyerhaeuser's extensive timberland holdings for clean, baseload energy production, supporting the growth of Weyerhaeuser's Climate Solutions business and meeting increasing electricity demand, particularly from AI and data centers. Hexagon Energy will lease approximately 145,000 acres of Weyerhaeuser's land for these developments.

A Tennessee woman has filed a lawsuit against MGM Resorts International, alleging negligence and failure to protect her from a spa employee who sexually assaulted her during a massage in 2024. The lawsuit claims that massage therapist Steven Thomas sexually assaulted her at the MGM Grand spa on September 7, 2024. The woman stated she had previously received massages from Thomas without incident.

AbbVie announced positive topline results from its Phase 3 LUNA clinical trial, demonstrating that its drug atogepant significantly reduced menstrual migraine days in adults. The oral CGRP receptor antagonist, administered for seven consecutive days over three menstrual cycles, achieved its primary endpoint with an average reduction of 1.20 migraine days compared to 0.40 days for the placebo group. Atogepant also showed statistically significant improvements in secondary endpoints, including overall headache burden, need for acute medication, functional disability, and cognitive function.